UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 24 25, 2026

KYMERA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-39460

81-2992166

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

Kymera Therapeutics, Inc. 500 North Beacon Street, 4th Floor Watertown, Massachusetts 02472 (Address of principal executive offices, including zip code)

500 North Beacon Street, 4th Floor

Watertown, Massachusetts 02472

(Address of principal executive offices, including zip code)

(857) 285-5300

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		~~TradeSymbol~~Trade Symbol(s)		Name of each ~~exchangeon~~exchange on which registered
Common Stock, $0.0001 par value per share		KYMR		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 57.0701. ~~Submission~~Regulation ofFD ~~Matters to a Vote of Security Holders~~Disclosure

On June 25, 2026, Kymera Therapeutics, Inc. (the “Company”) ~~held~~issued ~~its~~a ~~Annual~~press ~~Meeting of Shareholders on June 24~~release, ~~2026~~a ~~(the~~copy ~~“Annual Meeting”). At the Annual Meeting, the Company’s shareholders considered and voted on the three proposals set forth below, each~~ of which is ~~described~~furnished inherewith ~~greater~~as ~~detail~~Exhibit ~~in the Company’s Proxy Statement, filed with the Securities and Exchange Commission on April 29, 2026~~99. ~~The final voting results are set forth below~~1.

~~Proposal~~The information in this Item 7.01, including Exhibit 99.1 –attached ~~Election~~hereto, shall not be deemed “filed” for purposes of ~~Class~~Section ~~III~~18 ~~Director~~of ~~Nominees~~the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

~~The~~Item ~~shareholders of the Company elected Bruce Booth, D~~8.~~Phil~~01., ~~Nello~~Other Mainolfi, Ph.D., John Maraganore, Ph.D. and Elena Ridloff, CFA as Class III directors of the Company, each to hold office for a three-year term ending at the annual meeting of shareholders to be held in 2029 and until his or her successor has been duly elected and qualified or until his or her earlier death, resignation or removal. The results of the shareholders’ vote with respect to the election of the Class III directors were as follows: Events

	VotesFor	VotesWithheld	BrokerNon-Votes
Bruce Booth, D.Phil.	71,962,459	5,430,527	1,707,176
Nello Mainolfi, Ph.D.	73,411,316	3,981,670	1,707,176
John Maraganore, Ph.D.	72,501,958	4,891,028	1,707,176
Elena Ridloff, CFA	72,453,404	4,939,582	1,707,176

On June 25, 2026, the Company announced that it has completed enrollment in the global BROADEN2 Phase 2b trial of KT-621, its first-in-class, oral STAT6 degrader, for the treatment of moderate to severe atopic dermatitis (“AD”). Enrollment was completed in advance of prior expectations, and the Company expects this development to accelerate the timing of its anticipated topline data readout to year-end 2026, representing a potential advancement of six months relative to its prior expectation of releasing the readout in mid-2027. Subject to discussions with regulators, the Company expects to initiate Phase 3 trials in AD by mid-2027.

~~Proposal~~The 2disclosure –under ~~Non~~this Item 8.01 contains forward-~~Binding~~looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, ~~Advisory~~as ~~Vote~~amended, including, without limitation, implied and express statements about the Company’s expectations regarding strategy, business plans and objectives on ~~Compensation~~the development of KT-621, including the therapeutic potential, clinical benefits and safety thereof, the initiation of Phase 3 trials of KT-621 in patients with AD by mid-2027, and anticipated Phase 2b topline data readout of KT-621 in patients with moderate to severe AD expected by year-end 2026. The words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “expect,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target,” “upcoming” and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this Item 8.01 are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from any forward-looking statements contained in this Item 8.01, including, without limitation, risks associated with: uncertainties inherent in the initiation, timing and design of ongoing and future clinical trials, the availability and timing of data from ongoing and future clinical trials and the results of such trials, the ability to successfully demonstrate the safety and efficacy of drug candidates, the timing and outcome of planned interactions with and submissions to regulatory authorities, the availability of funding sufficient for the Company’s ~~Named~~operating ~~Executive~~expenses ~~Officers~~and capital expenditure requirements and other factors. These risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in the Company’s most recent Quarterly Report on Form 10-Q and in subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent the Company’s views only as of the date on which it was made and should not be relied upon as representing the Company’s views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

~~The~~Item ~~shareholders of the Company approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers~~9.01. ~~The results of the shareholders’ non-binding, advisory vote with respect to such approval were as follows:~~ Exhibits

Votes For		Votes Against		Abstain		BrokerNon-Votes
74,903,687		2,462,732		26,567		1,707,176

(d) Exhibits

Proposal 3 – Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm


Exhibit No.		Description

99.1		Press release issued by Kymera Therapeutics, Inc. on June 25, 2026.

104		Cover Page Interactive Data

The shareholders of the Company ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the shareholders’ vote with respect to such ratification were as follows:

Votes For		Votes Against		Abstain		BrokerNon-Votes
79,043,801		38,128		18,233		0

No other matters were submitted to or voted on by the Company’s shareholders at the Annual Meeting.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Kymera Therapeutics, Inc.

Date: June 24, 2026

/s/ Nello Mainolfi

Date: June 25, 2026

/s/ Nello Mainolfi

Nello Mainolfi, Ph.D.

President and Chief Executive Officer

Filing Compare · Kymera Therapeutics, Inc.